Pharmacokinetics and tolerability of MB12066, a beta-lapachone derivative targeting NAD(P)H:quinone oxidoreductase 1: two independent, double-blind, placebo-controlled, combined single and multiple ascending dose first-in-human clinical trials - Kim, Seokuee; Lee, SeungHwan; Cho, Joo-Youn; Yoon, Seo Hyun; Jang, In-Jin; Yu, Kyung-Sang (Drug design, development and therapy, 2017)
Keywords: Administration, Oral; Adult; Cancer; Clinical trials; Diabetes; Dose-Response Relationship, Drug; Double-Blind Method; Double-blind studies; Drug dosages; Electrocardiography; Enzyme kinetics; Exposure; First-in-human; Genotyping; Health care; Healthy Volunteers; Humans; Laboratories; Laboratory tests; Lapachone; Life sciences; Male; Medical research; Metabolic syndrome; Metabolism; Metabolites; Middle Aged; NAD; NAD(P)H Dehydrogenase (Quinone) - antagonists & inhibitors; NAD(P)H Dehydrogenase (Quinone) - metabolism; NADH; NADPH quinone oxidoreductase; Naphthoquinones - chemistry; Nicotinamide adenine dinucleotide; NQO1; Obesity; Oral administration; Original Research; Pharmacogenomics; Pharmacokinetics; Pharmacology; Phase 1; Physical examinations; Quinone oxidoreductase; Urine; Weight control; Young Adult; South Korea; pharmacokinetics; NQO1; Phase I; pharmacogenomics; first-in-human